Gilead Earnings Beat the Street Once Again
By Catherine Shaffer
Wednesday, October 30, 2013
A Gilead Sciences Inc. earnings report filled with confidence about the upcoming launch of sofosbuvir and solid bottom-line beats boosted the company’s stock by 4.6 percent Wednesday.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.